Li Y, Sheu C C, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study[J]. Lancet Oncol, 2010, 11(4): 321-330. [2]Saunders S, Paine-Saunders S, Lander A D. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain[J]. Dev Biol, 1997, 190(1): 78-93. [3]Okamoto K, Tokunaga K, Doi K, et al. Common variation in GPC5 is associated with acquired nephrotic syndrome[J]. Nat Genet, 2011, 43(5): 459-463. [4]Kim J C, Kim S Y, Cho D H, et al. Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers[J].Cancer Sci, 2010, 101(4): 1007-1013. [5]Williamson D, Selfe J, Gordon T, et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma[J]. Cancer Res, 2007, 67(1): 57-65. [6]Schraders M, Pfundt R, Straatman H M, et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization[J]. Blood, 2005, 105(4): 1686-1693. [7]Shin J G, Kim H J, Park B L, et al. Putative association of GPC5 polymorphism with the risk of inflammatory demyelinating diseases[J]. J Neurol Sci, 2013, 335(1/2): 82-88. [8]Li Y, Miao L, Cai H, et al. The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer[J]. Oncol Lett, 2013, 6(6): 1565-1572. [9]Yang X, Zhang Z, Qiu M, et al. Glypican-5 is a novel metastasis suppressor gene in non-small cell lung cancer[J]. Cancer Lett, 2013, 341(2): 265-273. [10]饶文, 余祖滨, 向颖, 等. GPC5基因在肺腺癌组织中差异表达和突变分析[J]. 第三军医大学学报, 2014, 36(11): 1153-1157. [11]De-Cat B, David G. Developmental roles of the glypicans[J]. Semin Cell Dev Biol, 2001, 12(2): 117-125. [12]Filmus J, Capurro M, Rast J. Glypicans[J]. Genome Biol, 2008, 9(5): 224. [13]Ambros V. The functions of animal microRNAs[J]. Nature, 2004, 431(7006): 350-355. [14]Zeringue H C, Constantine-Paton M. Post-transcriptional gene silencing in neurons[J]. Curr Opin Neurobiol, 2004, 14(5): 654-659. [15]Valsechi M C, Oliveira A B, Conceicao A L, et al. GPC3 reduces cell proliferation in renal carcinoma cell lines[J]. BMC Cancer, 2014, 14: 631. [16]郑大勇, 阮健, 刘斐烨, 等. RNA干扰GPC3基因表达影响肝癌细胞Huh-7凋亡的机制研究[J]. 热带医学杂志, 2011, 11(5): 516-519.
[2]
刘翩,王斌,吴国明.吉非替尼维持治疗晚期肺腺癌长期生存1例[J].第三军医大学学报,2012,34(15):1491. [2]刘瑞青,申淑景,马杰,等.肺腺癌组织中TTF-1和SPA的表达对EGFR突变的临床预测价值[J].第三军医大学学报,2012,34(22):2314. Liu Ruiqing,Shen Shujing,Ma Jie,et al.Clinical value of TTF-1 and SPA expression in predicting EGFR mutations in lung adenocarcinoma[J].J Third Mil Med Univ,2012,34(07):2314. [3]刘小军,张雪琳,李莎莎,等.172例肺腺癌脑转移影响因素的临床分析[J].第三军医大学学报,2013,35(01):73. Liu Xiaojun,Zhang Xuelin,Li Shasha,et al.Clinical analysis of influencing factors for 172 lung adenocarcinoma patients with brain metastasis[J].J Third Mil Med Univ,2013,35(07):73. [4]余祖滨,白莉,姚珂,等.SOCS3对肺腺癌细胞株A549迁移和侵袭能力的影响[J].第三军医大学学报,2008,30(07):588. YU Zu-bin,BAI Li,YAO Ke,et al.Effects of SOCS3 gene on migration and invasion of lung adenocarcinoma cell line A549[J].J Third Mil Med Univ,2008,30(07):588. [5]朱冰,杨建茹,付新平,等.GALV致融性糖蛋白转导肺腺癌细胞的抗肿瘤实验研究[J].第三军医大学学报,2007,29(18):1737. ZHU Bing,YANG Jian-ru,FU Xin-ping,et al.Antitumor effect of GALV membrane fusion glycoprotein on lung adenocarcinoma in vivo and in vitro[J].J Third Mil Med Univ,2007,29(07):1737. [6]庞华,罗弋,李少林.人源肺腺癌噬菌体抗体库的构建及初步筛选[J].第三军医大学学报,2008,30(22):2082. PANG Hua,LUO Yi,LI Shao-lin.Construction of and screening for phage antibody library of human lung adenocarcinoma[J].J Third Mil Med Univ,2008,30(07):2082. [7]白莉,祝蓉,陈智鸿,等.靶向EGFR基因的siRNA表达载体构建及其生物学效应的研究[J].第三军医大学学报,2005,27(23):2307. [8]熊玮,钱桂生,黄桂君.氯氨顺铂诱导耐药后肺腺癌细胞株生物学特性及染色体核型分析[J].第三军医大学学报,2005,27(22):2226. [9]郭芮伶,吴国明,戢福云,等.多西紫杉醇对肺腺癌多药耐药细胞A549/CDDP及其亲代细胞作用机制的初步研究[J].第三军医大学学报,2005,27(07):610. [10]张雪淋,原薇薇,傅华,等.HOXA10在肺腺癌中的过表达及其临床意义[J].第三军医大学学报,2013,35(05):468. Zhang Xuelin,Yuan Weiwei,Fu Hua,et al.Over-expression and clinical significance of HOXA10 in human lung adenocarcinoma[J].J Third Mil Med Univ,2013,35(07):468.
